![Klaus Schollmeier](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Klaus Schollmeier
Direktor/Vorstandsmitglied bei
HEIDELBERG PHARMA AG
Profil
Currently, Klaus Schollmeier is Chairman at Anergis SA, Eternygen GmbH, and TACALYX GmbH; Chairman-Supervisory Board at Inthera Bioscience AG; Member-Supervisory Board at Heidelberg Pharma AG, Minaris Regenerative Medicine GmbH, Novaliq GmbH; and Independent Member-Supervisory Board at CureVac NV.
Formerly, the roles include Chief Executive Officer at SuppreMol GmbH (2013–2015), Chairman at Santhera Pharmaceuticals Holding AG (2011–2012), Chairman at PCOVERY ApS, Managing Director at ING BHF-Bank AG, Senior Director-Biotechnology at BASF Bioresearch Corp.
(1989–1993), Director at Graffinity Pharmaceuticals AG, Principal at Knoll AG and Abbott GmbH (Germany), Research Associate Professor-Medical School at Boston University, General Manager at BASF Pharma (1996–1998), and Member-Supervisory Board at Modra Pharmaceuticals BV.
Education includes a doctorate from Heinrich-Heine-Universität Düsseldorf conferred in 1991.
Aktive Positionen von Klaus Schollmeier
| Unternehmen | Position | Beginn |
|---|---|---|
| CUREVAC | Direktor/Vorstandsmitglied | 22.06.2022 |
| HEIDELBERG PHARMA AG | Direktor/Vorstandsmitglied | 15.05.2025 |
Minaris Regenerative Medicine GmbH
 Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology Develops cell-based and gene therapy products | Direktor/Vorstandsmitglied | - |
Eternygen GmbH
 Eternygen GmbH Pharmaceuticals: MajorHealth Technology Engages in the research and development of drugs | Vorsitzender | - |
TACALYX GmbH
 TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services Develops therapeutics targeting cancer-specific carbohydrate antigens for metastatic malignant tumors | Vorsitzender | 05.11.2020 |
Inthera Bioscience AG
 Inthera Bioscience AG BiotechnologyHealth Technology Develops, manufactures small bio molecule therapies for solid tumors | Vorsitzender | - |
Anergis SA
 Anergis SA Pharmaceuticals: GenericHealth Technology Provides allergy vaccines | Vorsitzender | - |
Novaliq GmbH
 Novaliq GmbH Medical SpecialtiesHealth Technology Develops and markets drug delivery systems | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Klaus Schollmeier
| Unternehmen | Position | Ende |
|---|---|---|
ING BHF-Bank AG
 ING BHF-Bank AG Major BanksFinance Provides banking services | Corporate Officer/Principal | 06.12.2018 |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░ | - |
| ░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Klaus Schollmeier
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
74
Beziehungen ersten Grades
20
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 20 |
|---|---|
Abbott GmbH (Germany)
 Abbott GmbH (Germany) Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical, diagnostic, nutritional, and hospital products | Health Technology |
Knoll AG
 Knoll AG Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Boston University
 Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ING BHF-Bank AG
ING BHF-Bank AG Major BanksFinance Provides banking services | Finance |
Graffinity Pharmaceuticals AG
 Graffinity Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Specializes in chemical genomics pharmaceutical products | Health Technology |
Santhera Pharmaceuticals Holding AG
 Santhera Pharmaceuticals Holding AG Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for the treatment of neuromuscular diseases | Health Technology |
Heidelberg Pharma AG
 Heidelberg Pharma AG Pharmaceuticals: MajorHealth Technology Develops cancer therapies | Health Technology |
Heinrich-Heine-Universität Düsseldorf
 Heinrich-Heine-Universität Düsseldorf Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BASF Bioresearch Corp. | |
SuppreMol GmbH
 SuppreMol GmbH Pharmaceuticals: MajorHealth Technology Develops novel therapeutics for the treatment of autoimmune diseases | Health Technology |
Anergis SA
Anergis SA Pharmaceuticals: GenericHealth Technology Provides allergy vaccines | Health Technology |
BASF Pharma | |
Pcovery ApS
 Pcovery ApS Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of invasive fungal infections | Health Technology |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Engages in the research and development of drugs | Health Technology |
Novaliq GmbH
Novaliq GmbH Medical SpecialtiesHealth Technology Develops and markets drug delivery systems | Health Technology |
Minaris Regenerative Medicine GmbH
Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology Develops cell-based and gene therapy products | Health Technology |
Inthera Bioscience AG
Inthera Bioscience AG BiotechnologyHealth Technology Develops, manufactures small bio molecule therapies for solid tumors | Health Technology |
Modra Pharmaceuticals BV
 Modra Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Designs and develops oral formulations of commonly used anti-cancer drugs | Health Technology |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services Develops therapeutics targeting cancer-specific carbohydrate antigens for metastatic malignant tumors | Commercial Services |
CureVac NV
 CureVac NV BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops medicines based on messenger ribonucleic acid which includes prophylactic vaccines, oncology, and molecular therapies | Health Technology |
